Patent filing percentage after FDA approval among top selling U.S. 2022
As of August 2022, 92 percent of patent applications for the world's top selling drug Humira were filed after FDA approval in the United States, compared to 62 percent of patent applications filed after FDA approval of cancer drug Keytruda. This statistic illustrates the percentage of applications filed after FDA approval among top selling drugs in the United States.